SHR-3201
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 16, 2026
Hengrui’s potentially first-in-class Alzheimer’s drug cleared for China trial
(AllSci Corp)
- "Hengrui described SHR-3201 as designed to clear disease-associated biomarkers from the brain and slow cognitive decline and said no drug of the same class has been approved in China or internationally."
New trial • Alzheimer's Disease
1 to 1
Of
1
Go to page
1